Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4763-4767

  Wang, Zhi Dong ^a   Qiao, Yu Lei ^a   Tian, Xi Feng ^b   Zhang, Xue Qing ^a   Zhou, Shi Xiang ^a   Liu, Hai Xiang ^a   Chen, Ying ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b HEBEI UNITED UNIVERSITY   (China)

Author keywords

CBLB502; Pulmonary fibrosis; Radiation pneumonitis; Thoracic radiotherapy

Indexed keywords

EID: 84874007388     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4763     Document Type: Article

References (14)

1. Atkinson K, Vos B, Kang-Er Z, et al (1995).Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graftversus- host disease and survival after murine haematopoietic stem cell transplantation. Cytokines Mol Ther, 1, 47-55.
2. Brickey WJ, Neuringer IP, Walton W, et al (2012).MyD88 provides a protective role in long-term radiation-induced lung injury. Int J Radiat Biol, 88, 335-47.
3. Burdelya LG, Gleiberman AS, Toshkov I, et al (2012). Tolllike receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys, 83, 228-34.
4. Burdelya LG, Krivokrysenko VI, Tallant TC, et al (2008). An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-30.
5. Dale DC (2002). Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs, 62, S1-15.
6. Delanian S, Baillet F, Huart J, et al (1994). Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase (clinical trial). Radiother Oncol, 32, 12-20.
7. Epperly MW, Sikora CA, DeFilippi SJ, et al (2002).Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res, 157, 568-77.
8. Krivokrysenko V, Shakhov A, Singh V, et al (2012). Identification of G-CSF and IL-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure. J Pharmacol Exp Ther, 343, 497-508.
9. Kuwano K, Hagimoto N, Kawasaki M, et al (1999). Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J ClinInvest, 104, 13-9
10. Mehta V (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys, 63, 5-24.
11. Tallant T, Deb A, Kar N, et al (2004). Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. BMCMicrobiol, 4, 33.
12. Vijay-Kumar M, Aitken JD, Sanders CJ, et al (2008).Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol, 180, 8280-5.
13. Wynn TA (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest, 117, 524-9.
14. Zhou SX, Li FS, Qiao YL, et al (2012). Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner. Asian Pac J Cancer Prev, 13, 2807-12.